- Mounjaro (tirzepatide) overtook Augmentin as India’s highest-value drug in Oct 2025, generating ₹1 billion from just 85,000 units.
- Sales reached ₹3.33 billion within seven months of launch, with usage far outpacing rival Wegovy.
- Demand driven by rising obesity and diabetes, strong clinical results, and growing consumer awareness.
- India’s GLP-1 market expanded about 27% YoY and is projected to grow over 34% annually through 2030.
- Lilly deepening its India footprint with a US$1B investment and a new manufacturing hub in Hyderabad.
- Regulatory focus increasing as obesity indication for tirzepatide awaits approval and semaglutide faces a 2026 patent expiry.
